CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Anti-EGFR-Refractory Stage IV Colorectal Cancer Patients

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03087071
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:39.239700+00:00
Published At: 2026-01-12T00:00:00+00:00
Record Updated At: 2026-01-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["EGFR NP_005219.2:p.S492R", "KRAS Gene Mutation", "MAP2K1 Gene Mutation", "Metastatic Colorectal Adenocarcinoma", "Refractory Colorectal Adenocarcinoma", "Stage IV Colorectal Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-12"
protocolSection.identificationModule.nctId: "NCT03087071"
protocolSection.identificationModule.officialTitle: "A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Anti-EGFR-Refractory Stage IV Colorectal Cancer Patients"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.